Jefferies Maintains a 'Hold' on Gilead Sciences (GILD); Mixed ICAACJefferies maintains a 'Hold' on Gilead Sciences (NASDAQ: GILD) price target of $55.00.Analyst, Thomas Wei, said, "Phase 3 SINGLE data for Glaxo (NYSE: GSK) / Shionogi's dolutegravir, a competitor to GILD's elvitegravir/Stribild, was presented at ICAAC. These data were better-than-expected including the lack of resistance mutations in patients failing dolutegravir, a strong increase in CD4 cells, the lack of side effects, and an improvement in liver adverse events. We continue to believe dolutegravir will be competitive and pressure GILD's HIV franchise."
No comments:
Post a Comment